Sang Gyu Ju, Yong Chan Ahn, Yeong-bi Kim, Seung Gyu Park, Yoo-mi Choi, Cho Hee Na, Chae-Seon Hong, Dongryul Oh, Dong Yeol Kwon, Cheol Chong Kim, Dong Hyeon Kim
Cancer Res Treat. 2021;53(1):45-54. Published online September 15, 2020
Purpose This study aimed to reduce radiation doses to the tongue, a patient-specific semi-customized tongue immobilization device (SCTID) was developed using a 3D printer for helical tomotherapy (HT) of nasopharyngeal cancer (NPCa). Dosimetric characteristics and setup stability of the SCTID were compared with those of a standard mouthpiece (SMP).
Materials and Methods For displacement and robust immobilization of the tongue, the SCTID consists of four parts: upper and lower tooth stoppers, tongue guider, tongue-tip position guide bar, and connectors. With the SCTID and SMP, two sets of planning computed tomography and HT plans were obtained for 10 NPCa patients. Dosimetric and geometric characteristics were compared. Position reproducibility of the tongue with SCTID was evaluated by comparing with planned dose and adaptive accumulated dose of the tongue and base of the tongue based on daily setup mega-voltage computed tomography.
Results Using the SCTID, the tongue was effectively displaced from the planning target volume compared to the SMP. The median mucosa of the tongue (M-tongue) dose was significantly reduced (20.7 Gy vs. 27.8 Gy). The volumes of the M-tongue receiving a dose of 15 Gy, 30 Gy, and 45 Gy and the volumes of the mucosa of oral cavity and oropharynx (M-OC/OP) receiving a dose of 45 Gy and 60 Gy were significantly lower than using the SMP. No significant differences was observed between the planned dose and the accumulated adaptive dose in any dosimetric characteristics of the tongue and base of tongue.
Conclusion SCTID can not only reduce the dose to the M-tongue and M-OC/OP dramatically, when compared to SMP, but also provide excellent reproducibility and easy visual verification.
Citations
Citations to this article as recorded by
Salivary Gland Volume Changes and Dry Mouth Symptom Following Definitive Radiation Therapy in Oropharyngeal Cancer Patients—A Comparison of Two Different Approaches: Intensity-Modulated Radiation Therapy Versus Intensity-Modulated Radiation Therapy/Intens Seung Gyu Park, Yong Chan Ahn, Dongryul Oh, Kyungmi Yang, Sang Gyu Ju, Jin Man Kim, Dongyeol Kwon, Euncheol Choi, Han Gyul Yoon Cancers.2025; 17(3): 554. CrossRef
A Novel Immobilization Method for the Treatment of Head and Neck Cancer Using 3D Printing Christopher Szewczyk, Yixiang Liao, Samer Al-Khudari, Michael J. Jelinek, Ken Tatebe Practical Radiation Oncology.2024; 14(1): 20. CrossRef
Novel tongue-positioning device to reduce tongue motions during radiation therapy for head and neck cancer: Geometric and dosimetric evaluation Seongmoon Jung, Bitbyeol Kim, Sung Young Lee, Won Ick Chang, Jaeman Son, Jong Min Park, Chang Heon Choi, Joo Ho Lee, Hong-Gyun Wu, Jung-in Kim, Jin Ho Kim, Minsoo Chun PLOS ONE.2023; 18(9): e0291712. CrossRef
Dosimetric comparison between VMAT plans using the fast-rotating O-ring linac with dual-layer stacked MLC and helical tomotherapy for nasopharyngeal carcinoma Sang Gyu Ju, Yong Chan Ahn, Yeong-bi Kim, Jin Man Kim, Dong Yeol Kwon, Byoung Suk Park, Kyungmi Yang Radiation Oncology.2022;[Epub] CrossRef
Tongue Displacement Device in Decreasing the Radiation Dose to Tongue and Preventing Proton Beam Overshoot in Proton Therapy for Unilateral Head and Neck Cancer Chae-Seon Hong, Dongryul Oh, Sang Gyu Ju, Yong Chan Ahn, Yeong-bi Kim, Seyjoon Park, Woojin Lee Frontiers in Physics.2021;[Epub] CrossRef
Purpose The purpose of this study was to investigate the dosimetric benefits and treatment efficiency of carotid-sparing TomoHelical 3-dimensional conformal radiotherapy (TH-3DCRT) for early glottic cancer. Materials and Methods Ten early-stage (T1N0M0) glottic squamous cell carcinoma patients were simulated, based on computed tomography scans. Two-field 3DCRT (2F-3DCRT), 3-field intensity-modulated radiation therapy (3F-IMRT), TomoHelical-IMRT (TH-IMRT), and TH-3DCRT plans were generated with a 67.5-Gy total prescription dose to the planning target volume (PTV) for each patient. In order to evaluate the plan quality, dosimetric characteristics were compared in terms of conformity index (CI) and homogeneity index (HI) for PTV, dose to the carotid arteries, and maximum dose to the spinal cord. Treatment planning and delivery times were compared to evaluate treatment efficiency.
Results The median CI was substantially better for the 3F-IMRT (0.65), TH-IMRT (0.64), and TH-3DCRT (0.63) plans, compared to the 2F-3DCRT plan (0.32). PTV HI was slightly better for TH-3DCRT and TH-IMRT (1.05) compared to 2F-3DCRT (1.06) and 3F-IMRT (1.09). TH-3DCRT, 3F-IMRT, and TH-IMRT showed an excellent carotid sparing capability compared to 2F-3DCRT (p < 0.05). For all plans, the maximum dose to the spinal cord was < 45 Gy. The median treatment planning times for 2F-3DCRT (5.85 minutes) and TH-3DCRT (7.10 minutes) were much lower than those for 3F-IMRT (45.48 minutes) and TH-IMRT (35.30 minutes). The delivery times for 2F-3DCRT (2.06 minutes) and 3F-IMRT (2.48 minutes) were slightly lower than those for TH-IMRT (2.90 minutes) and TH-3DCRT (2.86 minutes). Conclusion TH-3DCRT showed excellent carotid-sparing capability, while offering high efficiency and maintaining good PTV coverage.
Citations
Citations to this article as recorded by
Accelerated three‐dimensional conformal radiotherapy for early‐stage glottic cancer in reducing dose to the internal carotid artery and pharyngeal constrictor muscles Kento Tomizawa, Atsushi Motegi, Hidekazu Oyoshi, Takeshi Fujisawa, Sadamoto Zenda, Yuzheng Zhou, Masaki Nakamura, Hidenari Hirata, Hidehiro Hojo, Shun‐ichiro Kageyama, Kouta Hirotaki, Kazuto Matsuura, Tetsuo Akimoto Head & Neck.2024; 46(2): 239. CrossRef
Dosimetric comparison between carotid-sparing IMRT and 3DCRT in early glottic cancer patients treated with definitive radiation therapy Harkirat Kaur, Niketa Thakur, Ramita Sharma, Meena Sudan, Neeraj Jain, Supreet Kaur, Priyanka Lehal Journal of Cancer Research and Therapeutics.2024; 20(1): 327. CrossRef
AAPM Task Group Report 306: Quality control and assurance for tomotherapy: An update to Task Group Report 148 Quan Chen, Yi Rong, Jay W. Burmeister, Edward H. Chao, Nathan A. Corradini, David S. Followill, X. Allen Li, An Liu, X. Sharon Qi, Hairong Shi, Jennifer B. Smilowitz Medical Physics.2023;[Epub] CrossRef
Application of error classification model using indices based on dose distribution for characteristics evaluation of multileaf collimator position errors Heesoon Sheen, Han-Back Shin, Hojae Kim, Changhwan Kim, Jihun Kim, Jin Sung Kim, Chae-Seon Hong Scientific Reports.2023;[Epub] CrossRef
Comparison of Carotid Artery Dose in Early-Stage Glottic Cancer Treated with 3D-Conformal, Helical-IMRT and VMAT B Pires, D Rothwell, I Guimarães, J Sousa, R Magalhães, T Serra, L Khouri, P Alves Forum of Clinical Oncology.2022; 13(3): 23. CrossRef
Preliminary Simulation Study of Carotid Artery and Pharyngeal Constrictor Muscle Sparing-Radiotherapy in Glottic Carcinoma Yurday Ozdemir, Ibrahim Acibuci, Ugur Selek, Erkan Topkan Technology in Cancer Research & Treatment.2020;[Epub] CrossRef
Dose-Volume Comparison of IMRT and PSPT Treatment Plans for Early-Stage Glottic Cancer Takahiro Kato, Nobukazu Fuwa, Masao Murakami International Journal of Particle Therapy.2020; 7(2): 42. CrossRef
Dosimetric Comparison of Four Different Techniques for Supraclavicular Irradiation in 3D-conformal Radiotherapy of Breast Cancer Razzagh Abedi Firouzjah, Amin Banaei, Bagher Farhood, Mohsen Bakhshandeh Health Physics.2019; 116(5): 631. CrossRef
Feasibility of hybrid TomoHelical- and TomoDirect-based volumetric gradient matching technique for total body irradiation Chae-Seon Hong, Min-Joo Kim, Jihun Kim, Kyung Hwan Chang, Kwangwoo Park, Dong Wook Kim, Min Cheol Han, Hong In Yoon, Jin Sung Kim, Ho Lee Radiation Oncology.2019;[Epub] CrossRef
Standardisation of Target Volume Delineation for Carotid-sparing Intensity-modulated Radiotherapy in Early Glottis Cancer D.M. Gujral, M. Long, J.W.G. Roe, K.J. Harrington, C.M. Nutting Clinical Oncology.2017; 29(1): 42. CrossRef
Carotid sparing intensity modulated radiotherapy on early glottic cancer: preliminary study Hoon Sik Choi, Bae Kwon Jeong, Hojin Jeong, Jin Ho Song, Jin Pyeong Kim, Jung Je Park, Seung Hoon Woo, Ki Mun Kang Radiation Oncology Journal.2016; 34(1): 26. CrossRef
Jae Myoung Noh, Jin Man Kim, Yong Chan Ahn, Hongryull Pyo, BoKyong Kim, Dongryul Oh, Sang Gyu Ju, Jin Sung Kim, Jung Suk Shin, Chae-Seon Hong, Hyojung Park, Eonju Lee
Cancer Res Treat. 2016;48(1):106-114. Published online February 12, 2015
Purpose This study was conducted to evaluate clinical outcomes following definitive concurrent chemoradiotherapy (CCRT) for patients with N3-positive stage IIIB (N3-IIIB) non-small cell lung cancer (NSCLC), with a focus on radiation therapy (RT) techniques. Materials and Methods From May 2010 to November 2012, 77 patients with N3-IIIB NSCLC received definitive CCRT (median, 66 Gy). RT techniques were selected individually based on estimated lung toxicity, with 3-dimensional conformal RT (3D-CRT) and intensity-modulated RT (IMRT) delivered to 48 (62.3%) and 29 (37.7%) patients, respectively. Weekly docetaxel/paclitaxel plus cisplatin (67, 87.0%) was the most common concurrent chemotherapy regimen.
Results The median age and clinical target volume (CTV) were 60 years and 288.0 cm3, respectively. Patients receiving IMRT had greater disease extent in terms of supraclavicular lymph node (SCN) involvement and CTV ≥ 300 cm3. The median follow-up time was 21.7 months. Fortyfive patients (58.4%) experienced disease progression, most frequently distant metastasis (39, 50.6%). In-field locoregional control, progression-free survival (PFS), and overall survival (OS) rates at 2 years were 87.9%, 38.7%, and 75.2%, respectively. Although locoregional control was similar between RT techniques, patients receiving IMRT had worse PFS and OS, and SCN metastases from the lower lobe primary tumor and CTV ≥ 300 cm3were associated with worse OS. The incidence and severity of toxicities did not differ significantly between RT techniques. Conclusion IMRT could lead to similar locoregional control and toxicity, while encompassing a greater disease extent than 3D-CRT. The decision to apply IMRT should be made carefully after considering oncologic outcomes associated with greater disease extent and cost.
Citations
Citations to this article as recorded by
Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Chong Han, Jingping Qiu, Lu Bai, Tingting Liu, Jun Chen, He Wang, Jun Dang International Journal of Radiation Oncology*Biology*Physics.2024; 119(4): 1179. CrossRef
“Mid-P strategy” versus “internal target volume strategy in locally advanced non small cell lung cancer: Clinical results from the randomized non-comparative phase II study Mid-P Line Claude, Camille Schiffler, Vanina Isnardi, Séverine Metzger, Sophie Darnis, Isabelle Martel-Lafay, Thomas Baudier, Simon Rit, David Sarrut, Myriam Ayadi Radiotherapy and Oncology.2024; 199: 110435. CrossRef
Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis Tingting Liu, Sihan Li, Silu Ding, Jingping Qiu, Chengbo Ren, Jun Chen, He Wang, Xiaoling Wang, Guang Li, Zheng He, Jun Dang eClinicalMedicine.2023; 64: 102246. CrossRef
The effect of radiotherapy and surgery on stage IIIA/B NSCLC patients treated with chemotherapy Y. Zeng, G. Wang, H. Zheng, Y. Wang, G. Ma, Z. Pang, J. Du International Journal of Radiation Research.2023; 21(3): 475. CrossRef
Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer Kyungmi Yang, Yang-Gun Suh, Hyunju Shin, Hongryull Pyo, Sung Ho Moon, Yong Chan Ahn, Dongryul Oh, Eunah Chung, Kwanghyun Jo, Jae Myoung Noh Life.2022; 12(2): 292. CrossRef
Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP) Luis E. Raez, Oscar Arrieta, Diego F. Chamorro, Pamela Denisse Soberanis-Piña, Luis Corrales, Claudio Martín, Mauricio Cuello, Suraj Samtani, Gonzalo Recondo, Luis Mas, Zyanya Lucia Zatarain-Barrón, Alejandro Ruíz-Patiño, Juan Esteban García-Robledo, Cami Frontiers in Oncology.2022;[Epub] CrossRef
Clinical Impact of Supraclavicular Lymph Node Involvement of Stage IIIC Non-Small Cell Lung Cancer Patients Sunmin Park, Won Sup Yoon, Mi Hee Jang, Chai Hong Rim Medicina.2021; 57(3): 301. CrossRef
Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer Hyunju Shin, Jae Myoung Noh, Hongryull Pyo, Yong Chan Ahn, Dongryul Oh Radiation Oncology Journal.2021; 39(1): 24. CrossRef
Comparaison dosimétrique et de la toxicité de la radiothérapie conformationnelle avec modulation d’intensité et de la radiothérapie conformationnelle tridimensionnelle des carcinomes bronchiques non à petites cellules F. Guillemin, L. Berger, M. Lapeyre, A. Bellière-Calandry Cancer/Radiothérapie.2021; 25(8): 747. CrossRef
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer Hyun Ae Jung, Jae Myoung Noh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Hongryull Pyo, Yong Chan Ahn, Keunchil Park Lung Cancer.2020; 146: 23. CrossRef
Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab Rocco Giannicola, Graziella D'Arrigo, Cirino Botta, Rita Agostino, Pietro Del Medico, Antonia Falzea, Vito Barbieri, Nicoletta Staropoli, Teresa Del Giudice, Pierpaolo Pastina, Valerio Nardone, Marika Monoriti, Graziella Calabrese, Giovanni Molecular and Clinical Oncology.2019;[Epub] CrossRef
Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy Min Wei, Qingqing Ye, Xuan Wang, Men Wang, Yan Hu, Yonghua Yang, Jiyuan Yang, Jun Cai Medicine.2018; 97(19): e0632. CrossRef
Dosimetric advantages of intensity modulated radiation therapy in locally advanced lung cancer John Boyle, Brad Ackerson, Lin Gu, Chris R. Kelsey Advances in Radiation Oncology.2017; 2(1): 6. CrossRef
Normal lung sparing Tomotherapy technique in stage III lung cancer Chae-Seon Hong, Sang Gyu Ju, Yong Chan Ahn, Gyu Sang Yoo, Jae Myoung Noh, Dongryul Oh, Kwangzoo Chung, Hongryull Pyo, Kwanghyun Jo Radiation Oncology.2017;[Epub] CrossRef
Superior sulcus non-small cell lung carcinoma: A comparison of IMRT and 3D-RT dosimetry Pierre Truntzer, Delphine Antoni, Nicola Santelmo, Catherine Schumacher, Pierre-Emmanuel Falcoz, Elisabeth Quoix, Gilbert Massard, Georges Noël Reports of Practical Oncology & Radiotherapy.2016; 21(5): 427. CrossRef
Cost of Intensity-modulated Radiation Therapy for Older Patients with Stage III Lung Cancer Minal S. Kale, Grace Mhango, Marcelo Bonomi, Alex Federman, Keith Sigel, Kenneth E. Rosenzweig, Juan P. Wisnivesky Annals of the American Thoracic Society.2016; 13(9): 1593. CrossRef